• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Why Is GameStop Surging By Around 10%? 22 Stocks Moving In Thursday's Pre-Market Session

    7/7/22 6:25:27 AM ET
    $ACRX
    $ALNA
    $ARTW
    $BBBY
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ACRX alert in real time by email

    Gainers

    • Allena Pharmaceuticals, Inc. (NASDAQ:ALNA) rose 39.6% to $0.2471 in pre-market trading after declining over 8% on Wednesday. Allena Pharmaceuticals recently announced rescheduling of special meeting to approve reverse stock split.
    • United Maritime Corporation (NASDAQ:USEA) rose 33.2% to $3.81 in pre-market trading. The company’s stock jumped 190% on Wednesday after completing its spin-off from Seanergy Maritime Holdings Corp.
    • AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) rose 27.4% to $0.3301 in pre-market trading after gaining around 4% on Wednesday.
    • Cryptyde, Inc. (NASDAQ:TYDE) rose 16.5% to $1.41 in pre-market trading. Cryptyde recently disclosed a corporate roadmap for the remainder of 2022 into 2023.
    • Dave Inc. (NASDAQ:DAVE) rose 16% to $0.84 in pre-market trading.
    • Veru Inc. (NASDAQ:VERU) rose 14.6% to $14.93 in pre-market trading. Veru shares gained 13% on Wednesday after the company announced the publication of the results from a Phase 3 COVID-19 study evaluating the efficacy and safety of oral sabizabulin for the treatment of hospitalized moderate-severe COVID-19 patients at high risk for ARDS and death in The New England Journal of Medicine Evidence.
    • Exicure, Inc. (NASDAQ:XCUR) rose 13.9% to $2.29 in pre-market trading.
    • Art's-Way Manufacturing Co., Inc. (NASDAQ:ARTW) rose 12.6% to $2.68 in pre-market trading. Art's-Way Manufacturing recently posted Q2 EPS of $0.04.
    • ZW Data Action Technologies Inc. (NASDAQ:CNET) rose 12.3% to $0.5399 in pre-market trading. ZW Data Action Tech, during May, reported a Q1 loss of $0.02 per share.
    • MIND Technology, Inc. (NASDAQ:MIND) rose 11.2% to $0.9273 in pre-market trading after the company announced that it received orders for sonar and source controller systems totaling approximately $7.7 million.
    • Connect Biopharma Holdings Limited (NASDAQ:CNTB) shares rose 9.7% to $0.9690 in pre-market trading.
    • Quotient Limited (NASDAQ:QTNT) rose 9.6% to $0.2730 in pre-market trading. Quotient Form4 filing showed that Director Zubeen Shroff reported purchase of 4.66 million shares at $0.30 pe share.
    • GameStop Corp. (NYSE:GME) rose 9.6% to $128.70 in pre-market trading after the company announced a stock split.
    • Bed Bath & Beyond Inc. (NASDAQ:BBBY) rose 9% to $4.87 in pre-market trading after several SEC filings showed recent insider buying.
    • Caterpillar Inc. (NYSE:CAT) rose 3.3% to $178.00 in pre-market trading.

    Don’t forget to check out our premarket coverage here .

    Losers

    • DiaMedica Therapeutics Inc. (NASDAQ:DMAC) fell 32.2% to $1.37 in pre-market trading after the company announced a clinical hold of its Phase 2/3 ReMEDy2 clinical trial for DM199.
    • CytomX Therapeutics, Inc. (NASDAQ:CTMX) fell 18% to $1.61 in pre-market trading after the company reported Phase 2 results for praluzatamab ravtansine in breast cancer. Piper Sandler and Mizuho downgraded the stock also.
    • Enjoy Technology, Inc. (NASDAQ:ENJY) shares fell 11.2% to $0.3720 in pre-market trading after jumping 35% on Wednesday.
    • Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) fell 11.1% to $0.7999 in pre-market trading. Titan Pharmaceuticals shares jumped 49% on Wednesday after the company announced FDA clearance of its IND application for nalmefene implant.
    • Revelation Biosciences, Inc. (NASDAQ:REVB) fell 9.2% to $1.09 in pre-market trading after jumping 44% on Wednesday.
    • Waitr Holdings Inc. (NASDAQ:WTRH) shares fell 8.1% to $0.2440 in pre-market trading after jumping 73% on Wednesday.
    • The Duckhorn Portfolio, Inc. (NASDAQ:NAPA) fell 6.3% to $19.42 in pre-market trading after the company reported a secondary offering of 5,000,000 shares of common stock.
    Get the next $ACRX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ACRX
    $ALNA
    $ARTW
    $BBBY

    CompanyDatePrice TargetRatingAnalyst
    Dave Inc.
    $DAVE
    2/9/2026Outperform
    Keefe Bruyette
    CytomX Therapeutics Inc.
    $CTMX
    1/20/2026$10.00Buy
    Guggenheim
    Veru Inc.
    $VERU
    12/18/2025$25.00Buy
    Canaccord Genuity
    Connect Biopharma Holdings Limited
    $CNTB
    12/1/2025$9.00Buy
    Lake Street
    DiaMedica Therapeutics Inc.
    $DMAC
    11/14/2025Overweight
    Cantor Fitzgerald
    Caterpillar Inc.
    $CAT
    11/14/2025Overweight
    Wells Fargo
    Caterpillar Inc.
    $CAT
    11/6/2025$660.00Hold → Buy
    HSBC Securities
    Connect Biopharma Holdings Limited
    $CNTB
    10/31/2025$10.00Buy
    BTIG Research
    More analyst ratings

    $ACRX
    $ALNA
    $ARTW
    $BBBY
    SEC Filings

    View All

    Revelation Biosciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - REVELATION BIOSCIENCES, INC. (0001810560) (Filer)

    2/26/26 4:25:26 PM ET
    $REVB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-K filed by Revelation Biosciences Inc.

    10-K - REVELATION BIOSCIENCES, INC. (0001810560) (Filer)

    2/26/26 4:06:19 PM ET
    $REVB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-K filed by Bed Bath & Beyond Inc.

    10-K - BED BATH & BEYOND, INC. (0001130713) (Filer)

    2/24/26 4:58:18 PM ET
    $BBBY
    Catalog/Specialty Distribution
    Consumer Discretionary

    $ACRX
    $ALNA
    $ARTW
    $BBBY
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for ENTADFI issued to VERU INC

    Submission status for VERU INC's drug ENTADFI (ORIG-1) with active ingredient FINASTERIDE;TADALAFIL has changed to 'Approval' on 12/09/2021. Application Category: NDA, Application Number: 215423, Application Classification: Type 4 - New Combination

    12/13/21 8:12:46 AM ET
    $VERU
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACRX
    $ALNA
    $ARTW
    $BBBY
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Cheng Lawrence bought $114,368 worth of shares (5,000 units at $22.87) (SEC Form 4)

    4 - GameStop Corp. (0001326380) (Issuer)

    1/26/26 9:06:47 AM ET
    $GME
    Electronics Distribution
    Consumer Discretionary

    President, CEO and Chairman Cohen Ryan bought $21,359,200 worth of shares (1,000,000 units at $21.36), increasing direct ownership by 3% to 38,347,842 units (SEC Form 4)

    4 - GameStop Corp. (0001326380) (Issuer)

    1/22/26 4:02:03 PM ET
    $GME
    Electronics Distribution
    Consumer Discretionary

    Director Attal Alain bought $259,577 worth of shares (12,000 units at $21.63), increasing direct ownership by 2% to 596,464 units (SEC Form 4)

    4 - GameStop Corp. (0001326380) (Issuer)

    1/21/26 6:32:09 PM ET
    $GME
    Electronics Distribution
    Consumer Discretionary

    $ACRX
    $ALNA
    $ARTW
    $BBBY
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider Khajehnouri Nima

    3 - Dave Inc./DE (0001841408) (Issuer)

    2/26/26 10:59:52 AM ET
    $DAVE
    Finance: Consumer Services
    Finance

    Group President Shurman Rodney Michael exercised 2,278 shares at a strike of $253.98 and sold $1,730,392 worth of shares (2,278 units at $759.61) (SEC Form 4)

    4 - CATERPILLAR INC (0000018230) (Issuer)

    2/24/26 7:36:37 PM ET
    $CAT
    Construction/Ag Equipment/Trucks
    Industrials

    Chief Accounting Officer Miller Josh covered exercise/tax liability with 8 shares, decreasing direct ownership by 3% to 301 units (SEC Form 4)

    4 - EXICURE, INC. (0001698530) (Issuer)

    2/19/26 2:27:21 PM ET
    $XCUR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACRX
    $ALNA
    $ARTW
    $BBBY
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Keefe Bruyette initiated coverage on Dave, Inc.

    Keefe Bruyette initiated coverage of Dave, Inc. with a rating of Outperform

    2/9/26 7:01:11 AM ET
    $DAVE
    Finance: Consumer Services
    Finance

    Guggenheim initiated coverage on CytomX Therapeutics with a new price target

    Guggenheim initiated coverage of CytomX Therapeutics with a rating of Buy and set a new price target of $10.00

    1/20/26 9:23:09 AM ET
    $CTMX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Canaccord Genuity initiated coverage on Veru with a new price target

    Canaccord Genuity initiated coverage of Veru with a rating of Buy and set a new price target of $25.00

    12/18/25 9:11:57 AM ET
    $VERU
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACRX
    $ALNA
    $ARTW
    $BBBY
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Dave to Report Fourth Quarter and Full Year 2025 Results and Participate in Upcoming Investor Conferences

    LOS ANGELES, CA, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Dave Inc. ("Dave" or the "Company") (NASDAQ:DAVE), one of the nation's leading neobanks, today announced its participation in two upcoming investor conferences following the Company's fourth quarter and full year 2025 earnings conference call on Monday, March 2, 2026, at 5:00 p.m. Eastern time. The earnings conference call and investor conference details are as follows: Earnings Conference Call Date: Monday, March 2, 2026Time: 5:00 p.m. Eastern timeConference Call Registration: linkWebcast: link The conference call will also be available for replay in the Events section of the Company's website, along with the transcript, at https://in

    2/26/26 4:15:00 PM ET
    $DAVE
    Finance: Consumer Services
    Finance

    DiaMedica Therapeutics to Participate in Upcoming March Investor Conferences

    DiaMedica Therapeutics Inc. (NASDAQ:DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restriction and acute ischemic stroke, today announced that company management will participate in three upcoming investment bank conferences. Details TD Cowen 46th Annual Healthcare Conference Boston, Massachusetts  Fireside chat with Rick Pauls, CEO, and Julie Krop, M.D., Chief Medical Officer, on Monday, March 2, 2026, at 11:50 a.m. Eastern Time (ET) Barclays 28th Annual Global Healthcare Conference  Miami, Florida  Fireside chat with Rick Pauls, CEO on Wednesday, March 10, 2026, at 10:00 a.m. ET Leerink Partners Global Health

    2/24/26 9:23:00 AM ET
    $DMAC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Bed Bath & Beyond, Inc. Reports Eighth Consecutive Quarter of Measurable Improvement Toward Profitability

    Q4 Reflects Strengthening Revenue Trends, Sustained Margin Expansion and a $118 Million Year-Over-Year Improvement in Operating Cash Flow Use Bed Bath & Beyond, Inc. (NYSE:BBBY), owner of Bed Bath & Beyond, Overstock, buybuy BABY, Kirkland's Home and a blockchain asset portfolio, today reported financial results for the fourth quarter and full year ended December 31, 2025. The Company delivered its eighth consecutive quarter of measurable improvement toward profitability, reflecting continued margin expansion, disciplined cost management and consistent progress across key operating metrics. The Company has successfully built the base of its business through disciplined retail executio

    2/23/26 4:01:00 PM ET
    $BBBY
    Catalog/Specialty Distribution
    Consumer Discretionary

    $ACRX
    $ALNA
    $ARTW
    $BBBY
    Leadership Updates

    Live Leadership Updates

    View All

    Cardiff Oncology Announces Executive Leadership Changes as it Transitions to Late-Stage Clinical Development

    SAN DIEGO, Jan. 27, 2026 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (NASDAQ:CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced a leadership transition designed to support the Company's next phase of growth and advancement toward late-stage development and key clinical and corporate milestones. Mani Mohindru, PhD, a member of Cardiff Oncology's Board of Directors since 2021 and a seasoned biotech executive, has been appointed interim Chief Executive Officer, effective immediately. Mark Erlander, PhD, Chief Executive Officer, and James Levine, Chief Financial Officer, have stepped down from their res

    1/27/26 7:00:00 AM ET
    $CRDF
    $CTMX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    Dave Inc. Appoints Nima Khajehnouri to Board of Directors; Announces Board Leadership Transitions

    LOS ANGELES, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Dave Inc. ("Dave" or the "Company") (NASDAQ:DAVE), one of the nation's leading neobanks, today announced that Nima Khajehnouri, a distinguished leader in artificial intelligence and data engineering, has joined its Board of Directors, effective immediately. Mr. Khajehnouri will serve as a member of the Company's Audit Committee. Imran Khan, who has served on the Board since August 2023, is stepping down in conjunction with this appointment. Mr. Khajehnouri brings more than two decades' experience of leading engineering at some of the world's most influential technology companies. He currently serves as Vice President of Engineering at Meta, h

    1/20/26 5:27:46 PM ET
    $DAVE
    Finance: Consumer Services
    Finance

    Caterpillar Announces Leadership Transition in Construction Industries

    IRVING, Texas, Jan. 14, 2026 /PRNewswire/ -- Caterpillar Inc. (NYSE:CAT) today announced that Tony Fassino, group president of Construction Industries, has elected to retire effective May 31, 2026, following 30 years with the company. Caterpillar veteran Rod Shurman has been appointed group president of Construction Industries effective Feb. 1, 2026, at which time Fassino will become group president, retired, for the remainder of the transition. "Tony's many contributions to Caterpillar and our customers' success over his accomplished 30-year career will leave a lasting impact

    1/14/26 4:05:00 PM ET
    $CAT
    Construction/Ag Equipment/Trucks
    Industrials

    $ACRX
    $ALNA
    $ARTW
    $BBBY
    Financials

    Live finance-specific insights

    View All

    Dave to Report Fourth Quarter and Full Year 2025 Results and Participate in Upcoming Investor Conferences

    LOS ANGELES, CA, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Dave Inc. ("Dave" or the "Company") (NASDAQ:DAVE), one of the nation's leading neobanks, today announced its participation in two upcoming investor conferences following the Company's fourth quarter and full year 2025 earnings conference call on Monday, March 2, 2026, at 5:00 p.m. Eastern time. The earnings conference call and investor conference details are as follows: Earnings Conference Call Date: Monday, March 2, 2026Time: 5:00 p.m. Eastern timeConference Call Registration: linkWebcast: link The conference call will also be available for replay in the Events section of the Company's website, along with the transcript, at https://in

    2/26/26 4:15:00 PM ET
    $DAVE
    Finance: Consumer Services
    Finance

    Bed Bath & Beyond, Inc. Reports Eighth Consecutive Quarter of Measurable Improvement Toward Profitability

    Q4 Reflects Strengthening Revenue Trends, Sustained Margin Expansion and a $118 Million Year-Over-Year Improvement in Operating Cash Flow Use Bed Bath & Beyond, Inc. (NYSE:BBBY), owner of Bed Bath & Beyond, Overstock, buybuy BABY, Kirkland's Home and a blockchain asset portfolio, today reported financial results for the fourth quarter and full year ended December 31, 2025. The Company delivered its eighth consecutive quarter of measurable improvement toward profitability, reflecting continued margin expansion, disciplined cost management and consistent progress across key operating metrics. The Company has successfully built the base of its business through disciplined retail executio

    2/23/26 4:01:00 PM ET
    $BBBY
    Catalog/Specialty Distribution
    Consumer Discretionary

    Veru Reports Fiscal 2026 First Quarter Financial Results and Clinical Program Progress

    -- Phase 2b PLATEAU clinical trial evaluating enobosarm in combination with semaglutide in older patients with obesity on track to initiate this quarter— --Company to host conference call and webcast today at 8:00 a.m. ET-- MIAMI, FL, Feb. 11, 2026 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ:VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and inflammatory diseases, today announced financial results for its fiscal 2026 first quarter ended December 31, 2025, and provided a corporate update. "The strategy for the next generation of obesity drugs should be a combination therapy with GLP-1 receptor agonists for

    2/11/26 6:30:00 AM ET
    $VERU
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACRX
    $ALNA
    $ARTW
    $BBBY
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13D filed by Exicure Inc.

    SC 13D - EXICURE, INC. (0001698530) (Subject)

    11/29/24 5:51:28 PM ET
    $XCUR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by CytomX Therapeutics Inc.

    SC 13G/A - CytomX Therapeutics, Inc. (0001501989) (Subject)

    11/14/24 4:26:32 PM ET
    $CTMX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by The Duckhorn Portfolio Inc.

    SC 13G/A - Duckhorn Portfolio, Inc. (0001835256) (Subject)

    11/14/24 4:22:50 PM ET
    $NAPA
    Beverages (Production/Distribution)
    Consumer Staples